Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics.
UTUC
nephroureterectomy
pentafecta
quality
upper tract urothelial carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Mar 2022
31 Mar 2022
Historique:
received:
05
03
2022
revised:
21
03
2022
accepted:
22
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Background: Measuring quality of care indicators is important for clinicians and decision making in health care to improve patient outcomes. Objective: The primary objective was to identify quality of care indicators for patients with upper tract urothelial carcinoma (UTUC) and to validate these in an international cohort treated with radical nephroureterectomy (RNU). The secondary objective was to assess the factors associated with failure to validate the pentafecta. Design: We performed a retrospective multicenter study of patients treated with RNU for EAU high-risk (HR) UTUC. Outcome measurements and statistical analysis: Five quality indicators were consensually approved, including a negative surgical margin, a complete bladder-cuff resection, the absence of hematological complications, the absence of major complications, and the absence of a 12-month postoperative recurrence. After multiple imputations and propensity-score matching, log-rank tests and a Cox regression were used to assess the survival outcomes. Logistic regression analyses assessed predictors for pentafecta failure. Results: Among the 1718 included patients, 844 (49%) achieved the pentafecta. The median follow-up was 31 months. Patients who achieved the pentafecta had superior 5-year overall- (OS) and cancer-specific survival (CSS) compared to those who did not (68.7 vs. 50.1% and 79.8 vs. 62.7%, respectively, all p < 0.001). On multivariable analyses, achieving the pentafecta was associated with improved recurrence-free survival (RFS), CSS, and OS. No preoperative clinical factors predicted a failure to validate the pentafecta. Conclusions: Establishing quality indicators for UTUC may help define prognosis and improve patient care. We propose a pentafecta quality criteria in RNU patients. Approximately half of the patients evaluated herein reached this endpoint, which in turn was independently associated with survival outcomes. Extended validation is needed.
Identifiants
pubmed: 35406553
pii: cancers14071781
doi: 10.3390/cancers14071781
pmc: PMC8997024
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Endourol. 2021 Mar;35(3):312-318
pubmed: 33081512
Eur Urol Focus. 2019 Mar;5(2):205-223
pubmed: 29154042
BJU Int. 2012 Jan;109(1):77-82
pubmed: 21631698
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Eur Urol. 2015 Jun;67(6):1122-1133
pubmed: 25488681
Cochrane Database Syst Rev. 2019 May 18;5:CD013160
pubmed: 31102534
Eur Urol. 2018 Feb;73(2):242-251
pubmed: 28342641
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
Urology. 2010 Jan;75(1):118-24
pubmed: 19864000
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
J Urol. 2013 Jan;189(1):36-42
pubmed: 23164381
J Clin Oncol. 2013 Apr 10;31(11):1422-7
pubmed: 23460707
J Urol. 2013 May;189(5):1662-9
pubmed: 23103802
J Urol. 2015 Dec;194(6):1567-74
pubmed: 26094807
Eur Urol. 2011 Oct;60(4):776-83
pubmed: 21798659
BJU Int. 2017 Feb;119(2):268-275
pubmed: 27322735
Eur Urol. 2012 Feb;61(2):245-53
pubmed: 21975249
J Urol. 2017 Mar;197(3 Pt 1):580-589
pubmed: 27670916
Eur Urol. 2014 Aug;66(2):181-3
pubmed: 24361259
J Urol. 2010 Aug;184(2):453-8
pubmed: 20620397
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Urol. 2013 Apr;189(4):1236-42
pubmed: 23079376
Int J Urol. 2010 Oct;17(10):848-54
pubmed: 20812922
Curr Opin Urol. 2021 Jul 1;31(4):291-296
pubmed: 33973537
Urol Oncol. 2019 Oct;37(10):758-764
pubmed: 31378586
Eur Urol. 2014 Jan;65(1):210-7
pubmed: 22579047
Syst Rev. 2014 Dec 23;3:150
pubmed: 25540016
BJU Int. 2020 Jan;125(1):64-72
pubmed: 31260600
World J Urol. 2015 Dec;33(12):1945-50
pubmed: 25947885
Transl Androl Urol. 2020 Aug;9(4):1786-1793
pubmed: 32944541
BJU Int. 2009 Feb;103(3):307-11
pubmed: 18990163
Eur Urol. 2010 Apr;57(4):575-81
pubmed: 19959276
Eur Urol Focus. 2019 May;5(3):457-466
pubmed: 29366854
Eur Urol. 2014 Mar;65(3):650-8
pubmed: 24070577
Curr Urol Rep. 2016 May;17(5):36
pubmed: 26968416
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Eur Urol. 2011 Oct;60(4):703-10
pubmed: 21684068
Clin Genitourin Cancer. 2018 Jun;16(3):e669-e675
pubmed: 29239844
Eur Urol. 2003 Dec;44(6):656-60
pubmed: 14644116
Eur Urol. 2011 May;59(5):702-7
pubmed: 21296482
Eur Urol. 2010 Oct;58(4):574-80
pubmed: 20637540